August 27, 2018
Over half the drug and medical device manufacturers restrict the supply of information on unapproved products and indications (“off-label information”) by their sales reps, a survey conducted by the Japan Pharmaceutical Industry Legal Affairs Association (Ihoken) has revealed. Ihoken’s compliance...read more